BAX Chart

1 Month

	Date	Diff
	2025-04-17	+3.85 %
Baxter International (BAX) stock rose by 3.85% likely due to positive market reactions surrounding Ligand Pharmaceuticals' merger with Channel Therapeutics, which aims to commercialize the innovative FDA-approved drug ZELSUVMI for treating molluscum contagiosum, a move seen as enhancing the company's growth potential and revenue opportunities.
	2025-04-14	+1.94 %
Baxter International's stock (BAX) saw a 1.94% increase due to the company's effective balance of short-term accountability and long-term strategic vision amidst ongoing market uncertainties, showcasing its commitment to sustainable growth even in turbulent times.
	2025-04-09	+9.94 %
Baxter International's (BAX) stock rose by 9.94% due to a combination of successful strategic change initiatives aimed at fostering innovation and addressing operational challenges within the organization, which were highlighted during a recent analysis of their performance improvements.
	2025-04-02	-1.09 %
Baxter International Inc. (NYSE:BAX) experienced a decrease of 1.09% in its stock price, attributed to factors such as analysts adjusting their price targets, short interest decreasing, and a generally stable market performance amid mixed valuation ratings from analysts.
	2025-04-01	-0.61 %
Baxter International Inc. (BAX) stock experienced a decline of 0.61% as it is evaluated among other undervalued healthcare stocks suggested by analysts, though the article does not provide specific reasons for the stock's drop. Baxter International Inc. (NYSE:BAX) stock fell by 0.61%, as the company received mixed ratings from analysts, with one sell rating, four holds, and five buys, reflecting market uncertainty and varying price targets from different brokerages.
	2025-03-18	-0.98 %
Baxter International's stock (BAX) fell by 0.98% following a downgrade in their Q1 2025 earnings estimates by Zacks Research, which reduced the expected earnings per share from $0.50 to $0.49, indicating weaker financial performance than previously anticipated.
	2025-03-12	-4.02 %
Baxter International (BAX) stock experienced a decline of -4.02% after analysts from Stifel Nicolaus and JPMorgan Chase & Co. lowered their price targets, reflecting concerns about the company's future performance despite a recent earnings beat.
	2025-03-10	-0.03 %
Baxter International (BAX) stock experienced a slight decline of 0.03%, and the drop could be attributed to fluctuating analyst ratings and target price adjustments, as well as overall market sentiments despite a positive earnings report in February.
	2025-03-06	+0.8 %
Baxter International (BAX) stock rose by 0.8% amidst Walgreens announcing its $10 billion sale to private equity firm Sycamore Partners, which suggests potential market confidence and interest in healthcare stocks that could benefit from this development.
	2025-03-04	-0.2 %
Baxter International (BAX) stock fell by 0.2% amid a consensus "Hold" rating from analysts, with recent price target reductions by firms like JPMorgan and Stifel Nicolaus suggesting concerns about the company's future performance.
	2025-02-25	+2.45 %
Baxter International (BAX) stock rose by 2.45% after Argus upgraded its rating from hold to buy, reflecting positive sentiment and new investment recommendations from various financial analysts.
	2025-02-21	+1.14 %
Baxter International's stock (NYSE:BAX) rose by 1.14% following a better-than-expected earnings report, where it posted $0.58 earnings per share, exceeding analyst predictions of $0.52.
	2025-02-20	+8.5 %
Baxter International's stock surged 8.5% due to reporting higher-than-expected profits for the latest quarter, driven by strong performance in its pharmaceuticals and medical products businesses.
	2025-02-19	-1.22 %
Baxter International (BAX) stock fell by 1.22% due to a downgrade from analysts, with StockNews.com moving it from a “buy” to a “hold” rating and reduced price targets from several firms, indicating concerns about the company's performance.
	2025-02-18	+1.23 %
Baxter International (BAX) stock rose 1.23% due to a combination of institutional trading activity, including modest selling by New York State Teachers Retirement System and new investments from various hedge funds, as well as the declaration of a quarterly dividend, which may have bolstered investor confidence despite recent downgrades from some analysts.
	2025-02-13	+1.09 %
Baxter International (BAX) stock rose by 1.09% last night due to positive market sentiment and potentially strong company performance indicators or news that were not detailed in the article.
	2025-02-11	-0.68 %
Baxter International (BAX) stock declined by 0.68% likely due to a mix of analyst downgrades and a cautious market response ahead of its upcoming earnings report scheduled for February 13th, where expectations for their performance are modest.
	2025-02-10	+0.62 %
Baxter International (BAX) stock rose 0.62% last night, potentially due to positive market perceptions stemming from strong performance comparisons with other medical companies, suggesting favorable investor sentiment in the healthcare sector.
	2025-02-07	-0.62 %
Baxter International Inc. (BAX) stock fell by 0.62% amidst a negative outlook from analysts, who have generally assigned a "Hold" rating and reduced price targets, indicating a cautious sentiment surrounding the company's financial performance and market conditions.
	2025-02-03	-2.83 %
Baxter International Inc. (BAX) stock declined by 2.83% following a reduction in institutional holdings and analysts downgrading the stock’s ratings and price targets, contributing to negative market sentiment.
	2025-01-13	+3.67 %
Baxter International Inc. (NYSE:BAX) stock rose by 3.67% due to its recent positive earnings report that exceeded analysts' expectations, along with various institutional investments, despite the mixed analyst recommendations regarding its overall performance.
	2024-12-17	+0.75 %
Baxter International (BAX) stock rose by 0.8% amidst a generally declining market, supported by the strength of the healthcare sector, alongside positive forecasts from companies like Pfizer, which helped bolster investor sentiment in that industry. Baxter International (BAX) stock increased by 0.75% amid a generally declining market, likely due to investors' positive response to its solid performance and profit outlook in the healthcare sector, which has shown resilience amidst broader economic uncertainties.
	2024-12-04	-0.33 %
Baxter International (BAX) stock fell by -0.33% due to weaker market performance compared to its competitor, Sigyn Therapeutics, despite having a stronger consensus rating and higher revenue.
	2024-12-03	-1.25 %
Baxter International (BAX) stock fell by -1.25% due to challenges faced by its new CEO in establishing a productive relationship with the board of directors, which can lead to dysfunction and impact overall company performance.
	2024-11-12	-1.14 %
Baxter International (BAX) stock fell by 1.14% following a downgrade to a "hold" rating from analysts and reduced price targets from several research firms.
	2024-11-08	-3.88 %
Baxter International (BAX) stock fell by 3.88% last night, likely due to broader market declines and negative investor sentiment stemming from disappointing quarterly earnings and guidance from other healthcare companies. Baxter International (BAX) stock fell by 3.88% last night amid a generally negative market sentiment affecting multiple stocks, likely influenced by broader concerns in the economy and industry-specific challenges.
	2024-11-01	+0.48 %
Baxter International (BAX) stock rose 0.48% last night as investors anticipate strong upcoming quarterly earnings, with analysts expecting the company to report earnings per share of $0.78, which is an improvement compared to previous periods.
	2024-10-30	-0.36 %
Baxter International (BAX) stock fell by 0.36% after a mix of investor activities, including a notable increase in holdings by Forsta AP Fonden and a series of lowered price targets and ratings from various brokerages, which may have dampened investor sentiment. Baxter International Inc. (BAX) stock experienced a decline of 0.36%, with analysts predominantly recommending a "Hold," which may reflect uncertainty about the company's performance and contributing to the stock’s decrease.